SCHEMBL956204

SCHEMBL956204

CCOC(=O)c1c(C)nn2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.55
PDE4D Q08499 1/20 0.55
ALDH1A1 P00352 10/20 0.51
KDM4E B2RXH2 9/20 0.51
HPGD P15428 7/20 0.51
GAA P10253 6/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
MAPK1 P28482 3/20 0.50
PDE4B Q07343 1/20 0.50
MAPT P10636 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ATM Q13315 1/20 0.49
NPSR1 Q6W5P4 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38666490 0.87 EGFR (0.52) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL21586237 0.87 EGFR (0.54) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL1780786 0.86 EGFR (0.53) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL16764335 0.86 TSHR (0.53) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL21586246 0.85 EGFR (0.52) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL16674798 0.83 EGFR (0.51) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL13860649 0.83 EGFR (0.78) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL30957108 0.83 ALDH1A1 (0.65) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL10931099 0.83 EGFR (0.51) EGFRPDE4DALDH1A1KDM4EHPGD
SCHEMBL10276357 0.82 EGFR (0.50) EGFRPDE4DALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. 2024-05-30 US disclosed
WO-2024073073-A2 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-04-04 WO disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
WO-2022101382-A1 PYRAZOLO DERIVATIVES AS HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS FOR USE AS ANTIVIRALS DRUG DISCOVERY AND CLINIC S.R.L. (IT) 2022-05-19 WO disclosed
US-20190330189-A1 ANTIBACTERIAL COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2019-10-31 US disclosed
EP-3110818-B1 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS UNIV MICHIGAN REGENTS (US) 2019-10-23 EP disclosed
EP-3110818-B1 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS UNIV MICHIGAN REGENTS (US) 2019-10-23 EP disclosed
US-10253044-B2 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-04-09 US disclosed
US-20180186768-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UC (IE) 2018-07-05 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed
US-5200415-A Serotonin receptor antagonists; antiemetics, antianxietics ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1993-04-06 US disclosed
EP-0483836-A1 Pyrazolo [1,5-a] pyridine-3-carboxylic acid derivatives, their preparation process and their use ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1992-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP EGFR 1500/4885PDE4D 867/4885ALDH1A1 344/4885
US-20190330189-A1 ANTIBACTERIAL COMPOUNDS FDPS, SQOR, NDUFS3 EGFR 3363/4885PDE4D 1731/4885ALDH1A1 1869/4885
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 EGFR 1084/4885PDE4D 1461/4885ALDH1A1 1687/4885
US-10253044-B2 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors BRD4, BRD3, BRD1 EGFR 1795/4885PDE4D 1227/4885ALDH1A1 981/4885
US-20180186768-A1 Antibacterial Compounds FDPS, SQOR, NDUFS3 EGFR 3363/4885PDE4D 1731/4885ALDH1A1 1869/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 EGFR 918/4885PDE4D 2928/4885ALDH1A1 728/4885
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF LRRK2, MAP3K20, MAP3K5 EGFR 1101/4885PDE4D 728/4885ALDH1A1 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.